When conventional
treatments fail
with entyvio*
*In clinical trials, patients had previously demonstrated an inadequate response to or intolerance of conventional treatments (corticosteroids or immunomodulators) and/or anti-tumor necrosis factor therapies.1
The ENTYVIO Pen for SC injection is a maintenance option after IV induction.
For adults with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD).
†Based on a quarterly analysis of Symphony medical and pharmacy claims with data from October 2022 through December 2023. Biologics include Cimzia® (certolizumab pegol; UCB, Inc.), Humira® (adalimumab; AbbVie Inc.), Skyrizi® (risankizumab-rzaa; AbbVie Inc.), Remicade® (infliximab; Janssen Biotech, Inc.), Stelara® (ustekinumab; Janssen Biotech, Inc.), Simponi® (golimumab; Janssen Biotech, Inc.), adalimumab biosimilars, and infliximab biosimilars. March 2024.
TREAT EARLY
The moment your adult patients with moderate
to severe Crohn’s or UC are not well-controlled
with conventional therapies, seek long-term
relief and remission. Patients achieved
remission at Week 52 vs placebo with the
ENTYVIO Pen or IV.1
Individual results may vary.
TREAT DIRECTLY
ENTYVIO helps address inflammation where it
occurs—in the gut.1 ENTYVIO specifically binds to
the α4β7 integrin and blocks its interaction with
MAdCAM-1, which is mainly expressed on the GI
tract endothelial cells.1-7
TREAT CONFIDENTLY
With 10 years of patient experience, 92%
unrestricted commercial coverage for ENTYVIO IV,
and growing coverage for the ENTYVIO Pen‡§‖
TREAT FLEXIBLY
With 2 options for maintenance treatment—the
ENTYVIO Pen for SC injection or IV infusions1¶
¶After at least 2 IV infusions.
‡Based on Symphony claims data from June 2014 to preliminary November 2023. February 2024.
§Unrestricted refers to coverage that does not require biologic step-edits. Data regarding current unrestricted commercial coverage for ENTYVIO as of January 2024 are derived from Managed Markets Insights & Technology (MMIT). March 2024.
‖Refers to covered commercial lives including unrestricted coverage and biologic step-edits. Data regarding current commercial coverage for the ENTYVIO Pen as of July 2024 are derived from MMIT. July 2024.
GI=gastrointestinal; IV=intravenous; MAdCAM-1=mucosal addressin cell adhesion molecule-1; SC=subcutaneous.
GEMINI I
GEMINI I was a randomized, double-blind, placebo-controlled study of
adult patients with moderately to severely active ulcerative colitis1
The foundational study of ENTYVIO
vs placebo
Patients achieved clinical response at Week 6 and clinical remission at Week 52 vs placebo.1
TRIAL
VARSITY, which studied ENTYVIO vs Humira® (adalimumab), was the first
head-to-head trial of biologics in moderate to severe ulcerative colitis8,9
ENTYVIO DEMONSTRATED SUPERIORITY
TO HUMIRA®*
In clinical remission at Week 52 in the overall population.8†
VARSITY was a double‑blind, double‑dummy, active‑controlled trial that compared ENTYVIO with Humira®* (adalimumab) in adults with moderately to severely active ulcerative colitis.
*Humira® is a registered trademark of AbbVie Inc., North Chicago, IL. For information about Humira®, please see AbbVie.com.
†Clinical remission was defined as a complete Mayo score of ≤2 points and no subscore >1 point. Superiority was demonstrated in the overall population. Individual results may vary.
Up to 7 years of consistent
safety data
Clinical trials evaluated safety in more than
3300 adults (UC, Crohn's, and healthy
volunteers).1
A separate open-label study of up to 7 years
demonstrated consistent results across
safety parameters.1,10,11*
*In a single-arm, open-label extension study, 2243 patients
received ENTYVIO IV with a median exposure of 1072 days (range 1 to
3412 days).10,11
Support for patients prescribed ENTYVIO
EntyvioConnect offers a range of programs tailored to help patients with access and affordability.
The content on this page has been written and
reviewed by Takeda.
IMPORTANT SAFETY INFORMATION
Contraindications
WARNINGS AND PRECAUTIONS
IMPORTANT SAFETY INFORMATION
Contraindications
ENTYVIO is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients.
Warnings and precautions
Adverse reactions
The most common adverse reactions (incidence ≥3% and ≥1% higher than placebo) were: nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, pain in extremities, and injection site reactions with subcutaneous administration.
Drug interactions
Because of the potential for increased risk of PML and other infections, avoid the concomitant use of ENTYVIO with natalizumab products and with TNF blockers. Upon initiation or discontinuation of ENTYVIO in patients treated with CYP450 substrates, monitor drug concentrations or other therapeutic parameters, and adjust the dosage of the CYP substrate as needed.
INDICATIONS
Adult Ulcerative Colitis (UC):
ENTYVIO is indicated in adults for the treatment of moderately to severely active UC.
Adult Crohn’s Disease (CD):
ENTYVIO is indicated in adults for the treatment of moderately to severely active CD.
Dosage forms & strengths:
Please click for Full Prescribing Information.
References: